A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combination Therapy in Subjects With Cystic Fibrosis
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combination Therapy in Subjects With Cystic Fibrosis
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
San Francisco, California 94143, United States
St. Petersburg, Florida 33701, United States
Boston, Massachusetts 02114, United States
Grand Rapids, Michigan 49546, United States
Columbia, Missouri 65212, United States
St Louis, Missouri 63110, United States
Toledo, Ohio 43606, United States
Nashville, Tennessee 37232, United States
Erlangen, Germany
Jena, Germany
Thessaloniki, Greece
Petach Tikvah, Israel
Bristol, United Kingdom